Rare and Orphan Diseases

1-16 of 48

Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart Matters
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
- Joban Vaishnav, MD
Counseling Patients on Disease Progression in ATTR-CM
Counseling Patients on Disease Progression in ATTR-CM
Heart Matters
Counseling Patients on Disease Progression in ATTR-CM
- Joban Vaishnav, MD
Rethinking Thromboembolic Risk in ATTR-CM Care
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart Matters
Rethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Matters
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Heart Matters
Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
AudioAbstracts
Rebalancing Amyloid in ATTR-CM: Emerging Therapeutic Insights
- Hallie Blevins, PhD
AI-Driven Advances in ATTR-CM Care
AI-Driven Advances in ATTR-CM Care
Heart Matters
AI-Driven Advances in ATTR-CM Care
- Frederick Ruberg, MD
Disease-Modifying Advances in ATTR-CM Management
Disease-Modifying Advances in ATTR-CM Management
Heart Matters
Disease-Modifying Advances in ATTR-CM Management
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstracts
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
- Ryan Quigley
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CM
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
- Ryan Quigley
- Ahmad Masri, MD, MS
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CM
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
- Ryan Quigley
- Kevin Alexander, MD
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
- Ryan Quigley
- Quan Bui, MD
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD

1/3

1-16 of 48

Title

Share on ReachMD

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy